Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zhonghua Nan Ke Xue ; 21(10): 892-5, 2015 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-26665676

RESUMO

OBJECTIVE: To investigate the efficacy and adverse effects of dapoxetine in the treatment of premature ejaculation. METHODS: We randomly assigned outpatients with premature ejaculation in the proportion of 2:1 to receive 30 mg dapoxetine on demand (n =78) or 50 mg sertraline qd for one month (n = 39). Follow-up was accomplished in 95 cases, 63 in the dapoxetine group and 32 in the sertraline group. We recorded the intravaginal ejaculatory latency time (IELT), clinical global impression of change (CGIC) score, and adverse reactions of the patients and compared them between the two groups. RESULTS: IELT was significantly increased in both the dapoxetine (from [0.87 ± 0.31] to [2.84 ± 0.68] min, P < 0.05) and the sertraline group (from [0.84 ± 0.28] to [2.71 ± 0.92] min, P < 0.05) after medication. Based on the CGIC scores in premature ejaculation, the rate of excellence or effectiveness was 36.5% in the dapoxetine and 37. 5% in the sertraline group, and the rate of improvement was 63.5% in the former and 71.9% in the latter. The incidence rates of dizziness, nausea, headache, and diarrhea were slightly higher (P > 0.05) while those of fatigue, somnolence, and dry mouth significantly higher (P < 0.05) in the sertraline than in the dapoxetine group. CONCLUSION: On-demand oral medication of dapoxetine is effective and well-tolerated for the treatment of premature ejaculation.


Assuntos
Benzilaminas/uso terapêutico , Naftalenos/uso terapêutico , Ejaculação Precoce/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Sertralina/administração & dosagem , Benzilaminas/efeitos adversos , Método Duplo-Cego , Ejaculação/efeitos dos fármacos , Ejaculação/fisiologia , Humanos , Masculino , Naftalenos/efeitos adversos , Pacientes Ambulatoriais , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Sertralina/efeitos adversos , Fatores de Tempo , Resultado do Tratamento
2.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 25(4): 348-50, 2009 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-19351509

RESUMO

AIM: To investigate the expression of IGF-IR and COX-2 in renal cell carcinoma(RCC). To explore the correlation among IGF-IR, COX-2 and PCNA expression. METHODS: Immunohistochemical staining was performed to detect the expression of IGF-IR, COX-2 and PCNA in 64 cases of RCC. RESULTS: The positive rates of IGF-IR expression and COX-2 expression were 60.9%(39/64) and 51.6%(33/64) in RCC respectively. The expressions of IGF-IR and COX-2 in RCC tissues were not related to the histological type of RCC (P>0.05), but they were related to and increased with the size and clinical stages of RCC (P<0.05). The expression of IGF-IR was related to pathological grades, but COX-2 was not. The expression of IGF-IR was positively related with the expression of COX-2 and PCNA respectively, but there was negative correlation between COX-2 and PCNA. CONCLUSION: The experiment suggests that IGF-IR and COX-2 may produce a synergetic effect in oncogenesis and progression of RCC. Detection of these genes has positive effects on early diagnosis, malignancy determination, prognosis and treatment of RCC.


Assuntos
Carcinoma de Células Renais/patologia , Proliferação de Células , Ciclo-Oxigenase 2/biossíntese , Neoplasias Renais/patologia , Receptor IGF Tipo 1/biossíntese , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Renais/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Renais/metabolismo , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Antígeno Nuclear de Célula em Proliferação/biossíntese , Carga Tumoral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...